STOCK TITAN
  1. Home
  2. News
  3. NMTC

NeuroOne Medical Technologies Corp - NMTC STOCK NEWS

Welcome to our dedicated news page for NeuroOne Medical Technologies (Ticker: NMTC), a resource for investors and traders seeking the latest updates and insights on NeuroOne Medical Technologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NeuroOne Medical Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NeuroOne Medical Technologies's position in the market.

News
NeuroOne® CEO Dave Rosa Featured on Bloomberg Technology
Rhea-AI Summary
NeuroOne Medical Technologies (NMTC) CEO Dave Rosa appeared on Bloomberg Technology to discuss the Company's latest developments in improving surgical care options for patients with neurological disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.15%
Tags
none
-
News
NeuroOne® Announces First Implant of OneRF™ Ablation Electrodes
Rhea-AI Summary
NeuroOne Medical Technologies announced the first implant of its OneRF™ Ablation electrode, a FDA-cleared thin-film, sEEG-guided RF system capable of recording electrical activity and ablating nervous tissue with temperature control. The system offers new treatment options for patients with neurological disorders, positioning the company as a market leader in multi-functional diagnostic and therapeutic electrode technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
none
-
News
NeuroOne® CEO Dave Rosa Featured on Fox Business Network’s Varney & Co.
Rhea-AI Summary
NeuroOne Medical Technologies (NMTC) CEO, Dave Rosa, appeared on Fox Business Network's Varney & Co. to discuss the company's new diagnostic and therapeutic device. The device aims to improve patient outcomes by reducing hospitalizations and surgical procedures, thus lowering costs. NeuroOne also achieved a milestone with the commercial launch of its OneRF™ Ablation System.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
none
News
NeuroOne® Initiates Limited Commercial Launch of OneRF™ Ablation System
Rhea-AI Summary
NeuroOne Medical Technologies announces the initiation of a commercial launch of its FDA-cleared OneRF™ Ablation System, the first thin-film electrode technology capable of recording electrical activity and ablating nervous tissue with temperature control. The system aims to improve surgical care options and outcomes for patients with neurological disorders, offering potential clinical benefits and reducing hospital stays and adverse events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.66%
Tags
none
-
News
NeuroOne® to Participate in the 36th Annual Roth Conference
Rhea-AI Summary
NeuroOne Medical Technologies Corporation (NMTC) will participate in the 36th Annual Roth Conference to engage with investors and analysts. The company's CEO and CFO will host meetings to discuss its medical technology solutions. The event will take place in Dana Point, California, offering networking opportunities for institutional investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.2%
Tags
conferences
-
News
NeuroOne Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
NeuroOne Medical Technologies Corporation (NMTC) announces an equity award under the Inducement Plan to a new employee, granting 65,000 shares at $1.07 per share. The award vests over ten years, with 25% vesting after one year and the rest quarterly.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.41%
Tags
none
News
NeuroOne® Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
Rhea-AI Summary
NeuroOne Medical Technologies Corporation (NMTC) reports strong financial results for Q1 FY 2024, with product revenue of $978,000, a significant increase from $115,000 in Q1 FY 2023. The company raised $2.8 million through an ATM Offering and received FDA clearance for its OneRF™ Ablation System. The CEO highlighted positive customer feedback for Evo® sEEG and strategic advancements in other programs. Despite the net loss of $3.3 million, the company remains optimistic about future milestones and commercial launches.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.4%
Tags
earnings
-
News
NeuroOne® to Report First Quarter Fiscal Year 2024 Financial Results and Provide Corporate Update on February 13
Rhea-AI Summary
NeuroOne Medical Technologies Corporation (NMTC) will host a conference call and webcast on February 13, 2024, to discuss its financial results for the first quarter of fiscal year 2024 and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
conferences earnings
-
News
NeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) announces fiscal fourth quarter and full fiscal year ended September 30, 2023 results. Q4 2023 product revenue of $742,000, up from $69,000 in Q4 2022. Full-year product revenue of $1,952,000, up from $171,000 in FY 2022. Completed $6M capital raise in July 2023. FDA clearance for OneRF Ablation System in December 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.05%
Tags
earnings
News
NeuroOne® Receives FDA 510(k) Clearance to Market its OneRF™ Ablation System
Rhea-AI Summary
NeuroOne Medical Technologies Corporation (NMTC) receives FDA 510(k) clearance for its OneRF Ablation System, the first FDA-cleared thin-film, sEEG-guided RF system capable of recording electrical activity and ablating nervous tissue with temperature control. The company targets a commercial launch in the first half of 2024, aiming to transform neurosurgery procedures and improve patient outcomes. The OneRF Ablation System is the company's third FDA 510(k)-cleared device, expanding its line of electrode technology to address patients requiring diagnostic brain mapping procedures as well as RF ablation using the same sEEG electrode. The current brain ablation market is estimated to be at least $100M worldwide and growing rapidly, with the potential to grow multifold based on large addressable patient populations with unmet clinical needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.94%
Tags
clinical trial
Stock NMTC logo
NeuroOne Medical Technologies Corp

Nasdaq:NMTC

NMTC Rankings

#4990 Ranked by Market Cap
#1989 Ranked by Stock Gains
N/A Ranked by Dividends

NMTC Stock Data

30.60M
19.57M
12.2%
25.75%
1.41%
Surgical Appliance and Supplies Manufacturing
Manufacturing
Link
United States
Eden Prairie

About NMTC

neuroone medical technologies corporation operates as a medical technology company. it focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (ceeg) and stereoelectroencephalography (seeg) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, parkinson's disease, dystonia, essential tremors, and other related brain related disorders. the company is based in eden prairie, minnesota.